Anti-IL-2 receptor monoclonal antibody (induction immunosuppression)

Basiliximab

Brand names: Simulect

Basiliximab is a chimeric monoclonal antibody used for prophylaxis of acute rejection in solid organ transplantation, particularly renal transplantation.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It binds the alpha chain (CD25) of the interleukin-2 receptor on activated T lymphocytes, blocking IL-2-driven T-cell proliferation and the immune response to the graft.

Prescribing in practice

Severe hypersensitivity and anaphylactic reactions can occur, so it must be given where resuscitation facilities are available.
It is used as part of an immunosuppressive regimen, typically alongside ciclosporin and corticosteroids.
As with all immunosuppression, it increases susceptibility to infection.

Monitoring

Monitor for hypersensitivity reactions around administration and for signs of infection and graft function thereafter.

Counselling the patient

This medicine is given by a transplant team to help prevent rejection of your new organ.
Report any signs of infection or allergic reaction promptly.
Continue all other anti-rejection medicines exactly as prescribed.

Evidence & guidelines

IL-2 receptor antagonists are established induction agents that reduce acute rejection in renal transplantation.

Reference: NICE TA99; KDIGO transplant; BTS/NHSBT; SmPC; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Curated clinical cross-links plus same-class fallbacks.

Calculators

Pathways